



17 September 2021

## Opyl to present at next week's IRD Invest

**Melbourne, Australia, Friday 17 September 2021, Opyl Limited (ASX:OPL) ("Opyl" or the "Company")** is pleased to announce Michelle Gallaher, Chief Executive Officer, will present at IR Department's *IRD Invest 2021* virtual investor conference on Thursday September 23, 2021 at 11.00am AEST (Sydney time).

The conference takes place on Wednesday 22 and Thursday 23 September with the overarching theme of "Addressing the need for change".

In keeping with the theme, day two will focus specifically on addressing new needs in patient care. Michelle will provide an update on OPL's recent developments and an overview of future plans including how the Company will address the latest medical needs and clinical developments.

*IRD Invest 2021* is free to attend and investors are invited to register ahead of time at this URL:

<https://www.irdepartment.com.au/site/ird-invest/technology/ird-invest-innovation-and-change>

You will receive a confirmation email with instructions on how to access the briefing once you have completed the registration form.

The Board has authorised this announcement for release to the ASX.

**-ENDS-**

For media enquiries: Laura Blue +61 416 699 925

For investor enquiries: [info@opyl.ai](mailto:info@opyl.ai)

[www.opyl.ai](http://www.opyl.ai)

Opyl is a new generation Australian company that provides leading biopharma and health organisations access to emerging AI-assisted technologies and real-world data insights to understand and improve healthcare design, development, and delivery.

Opyl works at the intersection of clinical trials, artificial intelligence, and social media.

Our key offering for biopharma, medtech, government and healthcare organisations:

- clinical trial recruitment and retention solutions
- clinical trial predictive analytics
- deep social media insights

Our vision is to improve health and wellness by optimising data assets and digital activation to advance technologies for life.

Follow Opyl on Twitter (@Opylai), LinkedIn and Facebook